Cytotoxic T cells are immune cells that find and kill infected, damaged, or cancerous cells in your body. They carry the surface protein CD8, which is why they’re often called CD8+ T cells. Unlike antibodies, which neutralize threats floating in your bloodstream, cytotoxic T cells deliver a direct, targeted kill to individual cells that have gone wrong. They’re one of the most precise weapons your immune system has.
How They Identify Their Targets
Nearly every cell in your body displays small fragments of its internal proteins on its surface, like a name tag showing what’s happening inside. These fragments sit in a molecular holder called MHC class I. When a cell is healthy, the fragments are normal and cytotoxic T cells ignore it. But when a cell is infected by a virus or has become cancerous, abnormal protein fragments appear on that holder, essentially advertising that something has gone wrong inside.
Each cytotoxic T cell carries a unique receptor on its surface that fits one specific abnormal fragment, like a lock and key. When the receptor finds its match, the CD8 protein on the T cell grabs onto the MHC class I molecule to stabilize the connection and confirm the target. This system means cytotoxic T cells only kill cells displaying the exact fragment they’re programmed to recognize, leaving healthy neighboring cells unharmed.
How They Kill
Once a cytotoxic T cell locks onto a target, it forms a stable, tight seal with the infected cell and delivers a lethal payload from tiny internal packages called granules. The process relies on two key proteins working together. The first, perforin, punches holes in the target cell’s outer membrane. The second, granzyme B, slips through those holes and triggers a self-destruct sequence inside the cell.
Granzyme B works by activating the cell’s own death machinery. It triggers a chain reaction that causes the target cell’s mitochondria (its energy-producing structures) to release a signal that commits the cell to death. The cell essentially dismantles itself from the inside in a controlled process called apoptosis. This is cleaner than the cell simply bursting open, which would spill its contents and cause inflammation in surrounding tissue.
Cytotoxic T cells also have a backup killing method. They can activate a death receptor on the target cell’s surface, flipping a molecular “off switch” that triggers the same self-destruct process through a different route. Having multiple killing strategies makes them effective even when one pathway is partially blocked.
Beyond Killing: Cytokine Signals
Destroying infected cells isn’t the only thing cytotoxic T cells do. When activated, they can take one of three paths: release their killing granules, trigger the death-receptor pathway, or secrete signaling molecules called cytokines. In practice, many cytotoxic T cells do all three at once.
The two main cytokines they produce are IFN-gamma and TNF-alpha. IFN-gamma acts as an alarm signal that puts nearby cells into a heightened defensive state, making them harder for viruses to infect. It also recruits other immune cells to the area. TNF-alpha amplifies inflammation and can directly weaken certain pathogens. Cytotoxic T cells that produce multiple cytokines simultaneously tend to be the most effective at clearing infections. Research on parasitic infections has shown that patients who recovered had significantly higher numbers of these multifunctional T cells compared to those with ongoing disease.
From Inactive to Armed: Activation
Cytotoxic T cells don’t start out ready to kill. A newly made (naive) CD8+ T cell circulates through your body in an inactive state, waiting to encounter its matching antigen. That first encounter typically happens when a specialized immune cell called a dendritic cell presents the antigen to the T cell, essentially showing it what to look for.
Once a naive cytotoxic T cell recognizes its target antigen, it rapidly transforms. Within about three days, it ramps up production of receptors for IL-2, a growth-promoting signal. The activated T cell also starts producing IL-2 itself, creating a feedback loop that drives it to divide rapidly. A single activated cell can generate thousands of copies of itself within days, building an army of identical cells all tuned to the same threat.
The strength of the IL-2 signal during this expansion phase determines the cell’s fate. Cells receiving strong IL-2 signaling become aggressive, short-lived effector cells built to kill as many targets as possible right now. Cells receiving weaker IL-2 signals take a different path, becoming long-lived memory cells that stick around for future encounters.
Memory Cells and Long-Term Protection
After an infection clears, most of the expanded cytotoxic T cells die off. But a subset survives as memory T cells, and these can persist for decades. This is why you’re often immune to diseases you’ve already fought off or been vaccinated against: your body retains a reserve of T cells that remember the threat and can reactivate far faster than building a response from scratch.
Memory T cells aren’t simply sitting dormant. Research tracking these cells in blood, bone marrow, and lymph nodes has found that they continuously circulate and divide at a steady rate, renewing themselves rather than relying on an exceptionally long individual cell lifespan. This constant self-renewal is what maintains immune memory over a lifetime.
Their Role in Fighting Cancer
Cancer cells carry abnormal proteins that can appear on MHC class I molecules, making them visible to cytotoxic T cells. When these T cells infiltrate a tumor, they’re called tumor-infiltrating lymphocytes, and their presence is often a positive sign in cancer prognosis. The transferred or naturally arriving T cells must recognize tumor-specific antigens with enough precision to attack the cancer while minimizing damage to healthy tissue.
Tumors, however, fight back. One of the most common escape strategies is for cancer cells to stop displaying their MHC class I molecules altogether, effectively hiding their abnormal proteins and becoming invisible to cytotoxic T cells. This is one reason why cancers can progress even in people with otherwise healthy immune systems. Modern immunotherapy drugs work in part by countering these evasion tactics or by boosting the T cells’ ability to find and kill tumor cells despite the hostile environment inside a tumor.
When Cytotoxic T Cells Stop Working: Exhaustion
In chronic infections and cancer, cytotoxic T cells can enter a state called exhaustion. Exhausted T cells lose their ability to produce cytokines, kill infected cells, and multiply. They’re still present, but they’ve essentially been worn down by continuous stimulation without resolution.
Exhaustion shows up as a buildup of inhibitory receptors on the cell surface, particularly PD-1 and Tim-3. In studies of chronic viral infection, 65% to 80% of virus-specific CD8+ T cells in various organs expressed both PD-1 and Tim-3 simultaneously, and cells carrying both markers were more severely impaired than those with only one. These double-positive cells produced less IFN-gamma, less TNF-alpha, and less IL-2, and they divided more slowly.
This discovery led directly to a class of cancer drugs called checkpoint inhibitors. By blocking PD-1, Tim-3, or both, these treatments essentially release the brakes on exhausted T cells. In animal studies, blocking PD-1 alone increased the virus-specific T cell population by about fivefold and reduced viral levels by about fourfold. Blocking both PD-1 and Tim-3 together was even more effective, producing a nearly sevenfold expansion of T cells and a sixfold drop in viral levels.
How They Differ From Natural Killer Cells
Natural killer (NK) cells also destroy infected and cancerous cells, so they’re easy to confuse with cytotoxic T cells. The key difference is in how they choose their targets. Cytotoxic T cells use a highly specific receptor that recognizes one particular antigen fragment on MHC class I. Each T cell is custom-built for a single target. NK cells use a broader set of built-in receptors and are actually triggered when a cell is missing its MHC class I molecules, the same molecules cytotoxic T cells depend on.
This makes the two cell types complementary. If a virus or cancer causes a cell to hide its MHC class I (dodging cytotoxic T cells), that same change makes it more visible to NK cells. The physical interaction between the cells and their targets also differs: cytotoxic T cells form a tight, stable connection with the cells they’re killing, while NK cells make briefer, more transient contact before moving on to the next target.